0.0001
0.0000
(0.00%)
At close: January 29 at 3:00:00 PM EST
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Raul Silvestre Esq. | CEO, CFO, President, Principal Accounting Officer & Director | -- | -- | 1971 |
| Dr. John T. Isaacs Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor | -- | -- | -- |
| Dr. Samuel R. Denmeade M.D. | Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board | -- | -- | -- |
Rebus Holdings, Inc.
2629 Townsgate Road
Suite 215
Westlake Village, CA 91361
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1
Description
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Corporate Governance
Rebus Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available